Atherosclerotic Cardiovascular Disease, Colorectal Cancer, Inflammatory Bowel Disease, Type2 Diabetes Mellitus
Conditions
Keywords
NOD2 ligands
Brief summary
Nucleotide-binding oligomerization domain 2 (Nod2) signaling is critical for human health.To figure out the clinical relevance of NOD2 ligands, the investigators plan to evaluate the change of NOD2 ligands in inflammatory bowel diseases (IBD), CRC, atherosclerotic cardiovascular disease (ACVD), and type 2 diabetes mellitus (DM2 ).
Detailed description
Previous studies have shown that NOD2 gene mutants were associated with the Crohn's disease (CD), colorectal cancer (CRC) and many other diseases, suggesting the critical role of NOD2 signaling in human physiology and pathogenethesis. However, whether decreased NOD2 ligands also contributed to these diseases is unknown. In this study, the investigators plan to evaluate the change of NOD2 ligands in inflammatory bowel diseases (IBD), CRC, atherosclerotic cardiovascular disease (ACVD), and type 2 diabetes mellitus (DM2 ). For each of the patient, a sex- and age- matched control were chosen. Both the targeted metabolomics (LC-MS-MS methods) and NOD2-transfected cells co-expressing NF-κB luciferase reporters were used to test NOD2 ligands in the fecal and plasma samples.
Interventions
Observational studies, no intervention
Sponsors
National Natural Science Foundation of China
Zhujiang Hospital
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. Males or females at least 18-70 years old. 2. Patient able to give informed consent. 3. Patient with biopsy-proven CRC 4. Patient with biopsy-proven Crohn's disease (CD) or ulcerative colitis(UC), in the active phase. 5. patients with clinical diagnosed DM2 6. patients with ACVD:coronary angiography more than 50% stenosis in single or multiple vessels. 7. The age- and sex- matched health controls for each patient.
Exclusion criteria
1.Use antibiotics or probiotics within the last 2 weeks.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| NOD2 ligands in fecal and plasma | baseline | detected using targeted metabolomics (LC-MS-MS methods) and NOD2-transfected cells co-expressing NF-κB luciferase reporters |
Countries
China
Contacts
Primary ContactJie Gao, PHD
Outcome results
None listed